Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.95
- Piotroski Score 2.00
- Grade Equal-Weight
- Symbol (VACC)
- Company Vaccitech plc
- Price $5.00
- Changes Percentage (11.36%)
- Change $0.51
- Day Low $4.39
- Day High $5.09
- Year High $5.10
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.45
- Trailing P/E Ratio -3.448275862069
- Forward P/E Ratio -3.448275862069
- P/E Growth -3.448275862069
- Net Income $5.34 M
Income Statement
Quarterly
Annual
Latest News of VACC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Opinion | How to Talk About Fluoride, Vaccines and Raw Milk
Emily Oster, an economist and author of "Expecting Better" and "Cribsheet," discusses the importance of nuanced messaging in public health....
By The New York Times | 1 day ago -
Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax can proceed with a trial for its Covid-19 and influenza combined vaccine after FDA lifted a clinical hold. This development follows an adverse event that was later determined not related to th...
By MarketWatch | 3 days ago -
Jury awards $13 million to woman in Blue Cross Blue Shield of Michigan lawsuit over COVID-19 vaccine
A federal jury awarded $13 million to Lisa Domski who sued Blue Cross Blue Shield for firing her over refusing the COVID-19 vaccine due to religious beliefs. The jury verdict included $10 million in p...
By CBS News | 5 days ago
